This Chi­nese phar­ma filed for an IPO last Sep­tem­ber. Sev­en months and a $283M in­vest­ment lat­er, they are back at the HKEX

A sto­ried Chi­nese phar­ma play­er is aim­ing for a sec­ond shot at join­ing some pre-rev­enue biotechs on the Hong Kong Stock Ex­change, in an IPO that could fetch any­where be­tween $500 mil­lion and $1 bil­lion.

Han­soh Phar­ma­ceu­ti­cal Group re-filed its ap­pli­ca­tion af­ter first lay­ing out its pitch last Sep­tem­ber. While it had ini­tial­ly pen­ciled in $1 bil­lion, a source is now telling Reuters that the new range will be $500 mil­lion to $800 mil­lion — while an­oth­er in­di­cat­ed $800 mil­lion to $1 bil­lion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN